Insights on the Myasthenia Gravis Treatment Global Market to 2027 – Players Include Novartis, Pfizer and Shire Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Myasthenia Gravis Treatment – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Amid the COVID-19 crisis, the global market for Myasthenia Gravis Treatment estimated at US$ 1.3 Billion in the year 2020, is projected to reach a revised size of US$ 2 Billion by 2027, growing at a CAGR of 6.3% over the analysis period 2020-2027.

Medication, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$ 1.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Surgery segment is readjusted to a revised 4.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $352 Million, While China is Forecast to Grow at 9.7% CAGR

The Myasthenia Gravis Treatment market in the U.S. is estimated at US$ 352 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$ 430 Million by the year 2027 trailing a CAGR of 9.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 5.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.

Other Treatment Types Segment to Record 3.3% CAGR

In the global Other Treatment Types segment, USA, Canada, Japan, China and Europe will drive the 2.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$ 47.6 Million in the year 2020 will reach a projected size of US$ 58.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$ 270.2 Million by the year 2027, while Latin America will expand at a 4.2% CAGR through the analysis period.

Select Competitors (Total 34 Featured):

• AbbVie Inc.
• Alexion Pharmaceutical Inc.
• Avadel Pharmaceuticals plc
• Bausch Health Companies Inc.
• Baxter International, Inc.
• CSL Behring
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Grifols SA
• Novartis AG
• Pfizer, Inc.
• Shire plc
• Takeda Pharmaceutical Company Limited
• Valeant Pharmaceuticals International, Inc.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Impact of Covid-19 and a Looming Global Recession
• Global Competitor Market Shares
• Myasthenia Gravis Treatment Competitor Market Share Scenario Worldwide (in %): 2020E
• Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

• Total Companies Profiled: 34

For more information about this report visit https://www.researchandmarkets.com/r/kp4eft.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900